Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

Fig. 2

Treatment duration and afatinib dose in the safety analysis set (n = 38). Abbreviations: AE adverse event, CR complete response, NE not evaluable; OT other, PD progressive disease, PR partial response; QOD every other day, SD stable disease. aFor Patient 21, protocol treatment was discontinued due to disease progression; Thereafter, afatinib treatment beyond PD was discontinued due to skin disorders. bPatient 23 had no appropriate measurable lesion and was not included in the full analysis set

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us